Resignation of Mr. Deven Manohar Patil from the post of Chief Financial Officer
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mr. Deven Manohar Patil has resigned from the post of Chief Financial Officer (Key Managerial Personnel) of Asston Pharmaceuticals Ltd with effect from the close of business hours on October 13, 2025. He cited the pursuit of new career opportunities outside the company as the reason for his exit. The company has disclosed the resignation to BSE under SEBI LODR Regulation 30, but has not yet announced a replacement CFO. The intimation was signed by Saili Jayaram More, Whole Time Director.
A CFO departure at a small-cap pharma company can create short-term leadership uncertainty. Investors should watch for a timely announcement of a new CFO; an extended vacancy could weigh on sentiment and operational continuity.